检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:徐黎[1] 郑玥琪[1] 时桢 陈逸云[1] 邵慧江 陈建杰[1] XU Li;ZHENG Yueqi;SHI Zhen(Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China)
机构地区:[1]上海中医药大学附属曙光医院
出 处:《临床肝胆病杂志》2019年第8期1870-1873,共4页Journal of Clinical Hepatology
基 金:国家中医药管理局重点学科(中医传染病学科)(2010);陈建杰上海市明中医工作室(ZYSNXD-CC-MZY003)
摘 要:原发性胆汁性胆管炎(PBC)属于慢性胆汁淤积性自身免疫性肝病,若不予及时有效治疗可进展至肝纤维化、肝硬化,甚至终末期肝病。PBC治疗主要目的是预防终末期肝病的发生,并改善相关临床症状,提升患者生活质量。及时准确地风险分层可使难治性PBC患者受益。准确评估PBC患者的预后对于临床治疗至关重要。从宿主因素、实验室检查、药物治疗等方面综述近十年PBC预后因素的研究进展。Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease and may progress to liver fibrosis, liver cirrhosis, and even end-stage liver disease without timely and effective treatment. The main purpose of PBC treatment is to prevent the development of end-stage liver disease and improve related clinical symptoms and quality of life. Timely and accurate risk stratification may bring benefits to patients with refractory PBC, and an accurate evaluation of the prognosis of PBC patients is of vial importance for clinical treatment. This article reviews the research advances in the prognostic factors for PBC from the aspects of host factors, laboratory examination, and pharmacotherapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229